Measuring quality of life in patients with schizophrenia

PharmacoEconomics

Volumn 11, Issue 1, 1997, Pages 32-47

  Awad, A George ^a,b   Voruganti, Lakshmi N P ^c   Heslegrave, Ronald J ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE COST; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA;

EID: 0031015694     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711010-00005     Document Type: Review

References (73)

1. Shur E. The epidemiology of schizophrenia. Br J Hosp Med 1988; 40: 38-45
2. Eaton WW. Update on the epidemiology of schizophrenia. Epidemiol Rev 1991; 13: 320-8
3. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med 1992; Suppl. 20: 1-97
4. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522-5
5. Castle DJ, Wessely S, Murray RM. Sex and schizophrenia: effects of diagnostic stringency and associates with premorbid variables. Br J Psychiatry 1993; 162: 658-64
6. Mayer C, Kalterborn G, Naber D. Age of onset in schizophrenia: relations to psychopathology and gender. Br J Psychiatry 1993; 162: 665-71
7. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157-61
8. Goodpastor WA, Hare BK. Factors associated with multiple readmissions to an urban public psychiatric hospital. Hosp Community Psychiatry 1991; 42: 85-7
9. Pablo RY, Kadlac KE, Arboleda-Florez J. The readmission of psychotic patients to a general hospital psychiatry unit. Gen Hosp Psychiatry 1986; 8: 190-7
10. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medication: what are they and are they being achieved? CNS Drugs 1995; 4: 8-16
11. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609-18
12. Awad AG, Hogan TP, Voruganti LNP, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 123-3
13. Campbell A, Converse PE, Rogers WL. Subjective measures of well-being. Am Psychology 1976; 31: 117-24
14. Campbell A. The sense of well-being in America. New York: McGraw-Hill, 1981
15. McCall S. Human needs and the quality of life. In: Shea WR, King Farlow J, editors. Values and quality of life. New York: Science History Publications, 1976: 6-24
16. World Health Organization. The constitution of the World Health Organization. WHO Chronicle 1947; 1: 29
17. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619-26
18. Lamb RH. The new asylums in the community. Arch Gen Psychiatry 1979; 36: 129-34
19. Bachrach LL. Deinstitutionalization: an analytic review and sociological perspective. Rockville (MD): National Institute of Mental Health, 1976
20. Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982; 139: 1271-6
21. Lehman A. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369-73
22. Sullivan G, Wells K, Leake B. Quality of life of seriously mentally ill persons in Mississippi. Hosp Community Psychiatry 1991; 42: 752-4
23. Levitt AJ, Hogan TP, Bucosky CM. Quality of life in chronically mentally ill patients in day treatment. Psychol Med 1990; 20: 703-10
24. Corten P, Mercier C, Pelc I. Subjective quality of life: clinical model for assessment of rehabilitation treatment in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994; 29: 178-83
25. Lehman A, Possidente S, Hawker F. The quality of life of chronic patients in state hospital and in community residences. Hosp Community Psychiatry 1986; 37: 901-7
26. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-7
27. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 43: 262-5
28. Awad AG. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington: American Psychiatric Press, 1995: 735-47
29. Awad AG, Voruganti LNP, Heslegrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res. In press
30. Hogan TP, Awad HG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 1983; 13: 177-83
31. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-52
32. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477-280
33. Van Putten T, May PRA, Marder S, et al. Subjective response to antipsycholic drugs. Arch Gen Psychiatry 1981; 38: 187-90
34. Naber D, Walther A, Kirshere T, et al. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Vienna: Springer Verlag. 1995: 111-22
35. Davidhizar ER. Can clients with schizophrenia describe feelings and beliefs about taking medications? J Adv Nurs 1985; 10: 469-73
36. Glazer W, Sholomskas D, Williams D, et al. Chronic schizophrenics in the community: are they able to report their social adjustment? Am J Orthopsychiatry 1982; 52: 166-71
37. Voruganti LPN. Quality of life measurement in schizophrenia: a study of the credibility of patients' reports of self-rated quality of life (dissertation). Toronto: Institute of Medical Science, University of Toronto, 1996
38. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 37: 217-32
39. Lehman AF, Burns BJ. Severe mental illness in the community. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 357-66
40. Pathek DS, Pleil AM, Funderburk FR. Quality of life and outcome assessment techniques - a resource guide. Kalamazoo, Michigan: Pharmacia Upjohn Publications, 1995
41. Stein LI, Test MA. Alternative to mental health treatment: I. conceptual model, treatment program and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392-197
42. Malm U, May PRA, Deneker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 1981; 7: 477-87
43. Baker F, Intagliata J. Quality of life in the evaluation of community support systems. Eval Program Plann 1982; 5: 69-79
44. Bigelow DA, Brodsky G, Steward L, et al. The concept and measurement of quality of life as a dependent variable in evaluation of mental health services. In: Stahler GJ, Tash WR, editors. Innovative approaches to mental health evaluation. New York: Academic Press, 1982: 345-66
45. Lehman AF. Quality of life tool kit. Cambridge (MA): The Evaluation Center, 1995
46. Rosen A, Pavlovic H, Parker G. The life skills profile: a measure assessing function and disability in schizophrenia. Schizophr Bull 1989; 15: 325-34
47. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 1984; 10: 388-98
48. Hurry J, Stuart E, Bebbington P, et al. Socio-demographic associations with social disablement in a community sample. Soc Psychiatry 1983; 18: 113-21
49. Stuart E, Wykes T. Assessment schedules for chronic psychiatric patients. Psychol Med 1987; 17: 485-93
50. Becker M, Diamond R, Sainfort F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res 1993; 2: 239-51
51. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press, 1987
52. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-71
53. Diagnostic and Statistical Manual of Mental Disorders. 4th rev ed. Washington: American Psychiatric Association, 1994
54. Bergner M, Bobbit RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
55. Ware Jr JE. The SF-36 health survey in quality of life and pharmacoeconomics in clinical trials. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996: 337-45
56. McHorney CA, Ware Jr JE, Lu R, et al. The MOS 36-item Short-Form health survey (SF-36): III. tests of data quality, scaling assumptions and reliability across diverse patient groups. Med Care 1994; 32: 40-66
57. Chambers LW. The McMaster health index questionnaire. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996: 267-79
58. Voruganti LNP, Heslegrave RJ, Awad AG. Sickness Impact Profile (SIP) as a measure of patients' quality of life (QOL) in clinical trials involving antipsychotic drugs. 45th Annual Meeting of the American College of Neuropsychopharmacology; 1995 December 11-15; San Juan, Puerto Rico
59. Kozma A, Stones M. Social desirability in measures of subjective well-being: a systematic evaluation. J Gerontol 1987; 42: 56-9
60. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850-4
61. Revicki DA, Luce BR, Weschler JM, et al. Clozapine's cost-benefits [correspondence]. Hosp Community Psychiatry 1991; 42: 93-4
62. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 881-5
63. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261-4
64. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenics: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-90
65. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917-26
66. Lindstrom E, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402-12
67. Awad AG. Methodological and design issues in clinical trials of new neuroleptics - an overview. Br J Psychiatry 1993; 163 Suppl. 22: 51-7
68. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995; 31: 57-65
69. Data JL, Willke RJ, Barnes JR, et al. Re-engineering drug development: integrating pharmacoeconomic research into the drug development process. Psychopharmacol Bull 1995; 31: 67-73
70. Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics 1993; 4: 131-56
71. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals in Canada. 1st ed. Ottawa: CCOHTA, 1994
72. Ministry of Health. Ontario. Canada. Ontario guidelines for economic analysis of pharmaceutical products. Toronto. Ontario: 1994
73. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354-61